MedTrace Logo

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

NCT07035249 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-03-11

No results posted yet for this study

Summary

To evaluate the safety and efficacy of DCSZ11 in combination with standard therapy in patients with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

Low Dose DCSZ11

Patients will receive DCSZ11 at 600 mg every three weeks (Q3W).

DRUG

Medium Dose DCSZ11

Patients will receive DCSZ11 at 800 mg Q3W.

DRUG

High Dose DCSZ11

Patients will receive DCSZ11 at 1200 mg Q3W.

DRUG

Standard Treatment

The available standard treatment for head and neck cancer patients.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Xingchen Peng, Professor · West China Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-16
Primary Completion
2027-06-01
Completion
2027-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07035249 on ClinicalTrials.gov